These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 25566841)
1. [From the licensure of vaccines to the recommendation of the Standing Committee on Vaccination in Germany : criteria for the assessment of benefits and risks]. Pfleiderer M; Wichmann O Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):263-73. PubMed ID: 25566841 [TBL] [Abstract][Full Text] [Related]
2. The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials. Black S Expert Rev Vaccines; 2015; 14(12):1543-8. PubMed ID: 26414015 [TBL] [Abstract][Full Text] [Related]
3. Weighing the risks and benefits of vaccination. Glickman LT Adv Vet Med; 1999; 41():701-13. PubMed ID: 9890055 [TBL] [Abstract][Full Text] [Related]
4. Background paper to the recommendation for routine rotavirus vaccination of infants in Germany. Koch J; Wiese-Posselt M; Remschmidt C; Wichmann O; Bertelsmann H; Garbe E; Hengel H; Meerpohl JJ; Mas Marques A; Oppermann H; Hummers-Pradier E; von Kries R; Mertens T Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Jul; 56(7):957-84. PubMed ID: 23807405 [TBL] [Abstract][Full Text] [Related]
5. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy]. Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779 [TBL] [Abstract][Full Text] [Related]
6. The public health value of vaccines beyond efficacy: methods, measures and outcomes. Wilder-Smith A; Longini I; Zuber PL; Bärnighausen T; Edmunds WJ; Dean N; Spicher VM; Benissa MR; Gessner BD BMC Med; 2017 Jul; 15(1):138. PubMed ID: 28743299 [TBL] [Abstract][Full Text] [Related]
7. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Wharton M; Strikas RA; Harpaz R; Rotz LD; Schwartz B; Casey CG; Pearson ML; Anderson LJ; ; MMWR Recomm Rep; 2003 Apr; 52(RR-7):1-16. PubMed ID: 12710832 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516 [TBL] [Abstract][Full Text] [Related]
9. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines. Lopalco PL; DeStefano F Vaccine; 2015 Mar; 33(13):1541-8. PubMed ID: 25444788 [TBL] [Abstract][Full Text] [Related]
10. Evidence based vaccinology. Nalin DR Vaccine; 2002 Feb; 20(11-12):1624-30. PubMed ID: 11858871 [TBL] [Abstract][Full Text] [Related]
11. How to anticipate the assessment of the public health benefit of new medicines? Massol J; Puech A; Boissel JP; Therapie; 2007; 62(5):427-35. PubMed ID: 18206104 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood. Laupèze B; Hervé C; Di Pasquale A; Tavares Da Silva F Vaccine; 2019 Sep; 37(38):5670-5680. PubMed ID: 31420171 [TBL] [Abstract][Full Text] [Related]
14. Post-licensure rapid immunization safety monitoring program (PRISM) data characterization. Baker MA; Nguyen M; Cole DV; Lee GM; Lieu TA Vaccine; 2013 Dec; 31 Suppl 10():K98-112. PubMed ID: 24331080 [TBL] [Abstract][Full Text] [Related]
15. [Licensing procedures for human vaccines in Germany and Europe and the WHO prequalification program]. Grabski E; Hildt E; Wagner R Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Jan; 63(1):4-15. PubMed ID: 31776598 [TBL] [Abstract][Full Text] [Related]
16. Background paper to the recommendation for the preferential use of live-attenuated influenza vaccine in children aged 2-6 years in Germany. Falkenhorst G; Harder T; Remschmidt C; Terhardt M; Zepp F; Ledig T; Wicker S; Keller-Stanislawski B; Mertens T Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1557-64. PubMed ID: 24170085 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of childhood rotavirus vaccination in Germany. Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052 [TBL] [Abstract][Full Text] [Related]
18. Value of post-licensure data on benefits and risks of vaccination to inform vaccine policy: The example of rotavirus vaccines. Parashar UD; Cortese MM; Payne DC; Lopman B; Yen C; Tate JE Vaccine; 2015 Nov; 33 Suppl 4():D55-9. PubMed ID: 26122581 [TBL] [Abstract][Full Text] [Related]
19. Novel licensure pathways for expeditious introduction of new tuberculosis vaccines: a discussion of the adaptive licensure concept. Rustomjee R; Lockhart S; Shea J; Fourie PB; Hindle Z; Steel G; Hussey G; Ginsberg A; Brennan MJ Tuberculosis (Edinb); 2014 Mar; 94(2):178-82. PubMed ID: 24360811 [TBL] [Abstract][Full Text] [Related]
20. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2003 to 2006. Menzies R; Turnour C; Chiu C; McIntyre P Commun Dis Intell Q Rep; 2008 Jun; 32 Suppl():S2-67. PubMed ID: 18711998 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]